Valuation : Evogene Ltd.

Market Cap 6.92M 0 5.95M 5.61M 5.11M 9.56M 658M 9.6M 66.45M 25.68M 335M 25.99M 25.42M 1.06B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.92M 0 5.95M 5.61M 5.11M 9.56M 658M 9.6M 66.45M 25.68M 335M 25.99M 25.42M 1.06B EV / Sales 2026 *
4.66x
EV / Sales 2027 * 2.66x
Free-Float
72.14%
Yield 2026 *
-
Yield 2027 * -
1 day+0.13%
1 week-5.89%
Current month-6.74%
1 month-31.75%
3 months-9.83%
6 months-33.73%
Current year-48.44%
1 week 150
Extreme 150
173.1
1 month 150
Extreme 150
220.4
Current year 115.1
Extreme 115.1
410
1 year 115.1
Extreme 115.1
478.7
3 years 115.1
Extreme 115.1
3,700
5 years 115.1
Extreme 115.1
9,967
10 years 115.1
Extreme 115.1
33,500
Manager TitleAgeSince
Chief Executive Officer 60 30/11/2004
Corporate Officer/Principal - -
Corporate Officer/Principal - 31/12/2021
Director TitleAgeSince
Director/Board Member 60 -
Director/Board Member 77 02/06/2010
Chairman 60 31/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/26 Buy

Director

460,000 2.9111%
04/08/26 Buy

Director

800,000 5.0628%
01/04/26 Other

Executive/Senior Manager

20,000 0.2294%
Change 5-day change 1-year change 3-year change Capi.($)
+0.13%-5.89%-63.15%-94.51% 6.92M
+0.45%-7.01%-2.77%+11.08% 46.38B
+0.03%-2.99%+405.71%+522.33% 44.51B
-1.48%-6.07%+38.76%+18.49% 42.3B
-2.05%-5.68%+8.96%+63.48% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
+0.20%-4.10% - - 17.13B
-0.79%-1.17%+23.03%+109.94% 16.36B
+0.56%-2.91%+13.31%+31.64% 14.31B
-2.04%-6.21%+79.52%+37.81% 13.29B
Average -0.51%-3.08%+57.42%+82.51% 26.7B
Weighted average by Cap. -0.58%-3.04%+88.02%+124.96%

Financials

2026 *2027 *
Net sales 1.48M 0 1.28M 1.2M 1.1M 2.05M 141M 2.06M 14.25M 5.51M 71.94M 5.57M 5.45M 228M 2.6M 0 2.24M 2.11M 1.92M 3.59M 247M 3.61M 24.97M 9.65M 126M 9.76M 9.55M 399M
Net income -16.69M -0 -14.36M -13.52M -12.32M -23.05M -1.59B -23.14M -160M -61.93M -809M -62.66M -61.3M -2.56B -13.92M -0 -11.97M -11.27M -10.27M -19.22M -1.32B -19.3M -134M -51.64M -675M -52.25M -51.12M -2.14B
Net Debt - -
Logo Evogene Ltd.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Employees
38
Date Price Change Volume
10/09/26 ILA 155.00 +0.13% 78,071
09/09/26 ILA 154.80 -1.59% 16,551
08/09/26 ILA 157.30 -3.50% 72,502
07/09/26 ILA 163.00 -4.45% 158,105
04/09/26 ILA 170.60 +3.58% 49,286

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVGN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!